OncoCyte (NYSEAMERICAN:OCX) Issues Earnings Results, Misses Expectations By $0.06 EPS

OncoCyte (NYSEAMERICAN:OCX) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.06), MarketWatch Earnings reports.

Shares of NYSEAMERICAN:OCX traded up $0.11 during midday trading on Thursday, reaching $2.10. The company’s stock had a trading volume of 2,865 shares, compared to its average volume of 278,874. OncoCyte has a fifty-two week low of $1.50 and a fifty-two week high of $5.60.

In related news, major shareholder Broadwood Partners, L.P. acquired 1,391,466 shares of the stock in a transaction on Thursday, January 2nd. The stock was purchased at an average price of $2.16 per share, for a total transaction of $3,005,566.56. The acquisition was disclosed in a document filed with the SEC, which is available at this link.

A number of research firms have recently issued reports on OCX. Zacks Investment Research cut shares of OncoCyte from a “buy” rating to a “hold” rating in a research note on Wednesday, January 15th. Chardan Capital restated a “buy” rating and set a $7.75 price target on shares of OncoCyte in a research report on Thursday.

About OncoCyte

OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.

Read More: Stock Selection – What is cash flow?

Earnings History for OncoCyte (NYSEAMERICAN:OCX)

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.